Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer
NCT ID: NCT00049790
Last Updated: 2009-01-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
INTERVENTIONAL
2004-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology
NCT02204345
CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)
NCT00991796
Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer
NCT00806286
Study of Weekly Paclitaxel, Carboplatin and Irinotecan to Treat Lung Cancer
NCT00465907
Carboplatin and Paclitaxel in Treating Older Patients With Metastatic or Recurrent Unresectable Non-small Cell Lung Cancer
NCT00005059
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
recombinant human Angiostatin protein
paclitaxel
carboplatin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No previous chemotherapy for NSCLC
* Have one lesion that is bidimensionally measurable by physical exam, MRI, or CT greater than 1 cm in diameter
* Specified lab parameters
* Life expectancy of at least 12 weeks
* ECOG performance status of 0 or 1
* Understand requirements of study
* Agree to use effective contraceptive methods
Exclusion:
* Have CNS metastases
* Have any active cancer in addition ot NSCLC
* Participated in clinical trial involving conventional or investigational drugs within previous 4 weeks
* Have any contraindication to paclitaxel or carboplatin
* Have had Grade 3 or greater peripheral neuropathies
* Be pregnant or lactating
* Have a history of myocardial infarction or angina pectoris/angina in the last 6 months
* Have had significant (30 mL or more) hemoptysis with the past 3 months
* Have an active infection
* Have a history of bleeding diathesis, hypercoagulable condition, or an active bleeding disorder
* Be receiving concurrent treatment with therapeutic doses of heparin or coumadin
* Have had major surgery within 4 weeks of stating therapy
* Have additional uncontrolled serious medical conditions or psychiatric illness
* Received rhAngiostatin in other clinical protocols
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CASI Pharmaceuticals, Inc.
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Indiana Cancer Pavilion, Indiana University
Indianapolis, Indiana, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ANG-CL-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.